Table 1 Baseline patient characteristics at the start of maintenance therapy
Characteristic | All (n = 120) | ICIs (n = 38) | ICIs + Pem (n = 82) | P |
|---|---|---|---|---|
Age | ||||
  ≥ 65 | 53 (44.2) | 20 (52.6) | 33 (40.2) | 0.204 |
  < 65 | 67 (55.8) | 18 (47.4) | 49 (59.8) |  |
Gender | ||||
 Male | 85 (70.8) | 27 (71.1) | 58 (70.7) | 0.971 |
 Female | 35 (29.2) | 11 (28.9) | 24 (29.3) |  |
Smoking | ||||
 Yes | 75 (62.5) | 23 (60.5) | 52 (63.4) | 0.761 |
 No | 45 (37.5) | 15 (39.5) | 30 (69.3) |  |
ECOG PS | ||||
 0 | 42 (35.0) | 13 (34.2) | 29 (35.3) | 0.902 |
 1 | 78 (65.0) | 25 (65.8) | 53 (64.6) |  |
Brain metastasis | ||||
 Yes | 17 (14.2) | 3 (7.9) | 14 (17.1) | 0.180 |
 No | 103 (85.8) | 35 (92.1) | 68 (82.9) |  |
Liver metastasis | ||||
 Yes | 11 (9.2) | 3 (7.9) | 8 (9.8) | 1.000 |
 No | 109 (90.8) | 35 (92.1) | 74 (90.2) |  |
Intrathoracic metastasis | ||||
 Yes | 79 (65.8) | 26 (68.4) | 53 (64.6) | 0.684 |
 No | 41 (34.2) | 12 (31.6) | 29 (35.4) |  |
Bone metastasis | ||||
 Yes | 44 (36.7) | 12 (31.6) | 32 (39.0) | 0.431 |
 No | 76 (63.3) | 26 (68.4) | 50 (61.0) |  |
Platinum | ||||
 Cisplatin | 33 (27.5) | 10 (26.3) | 23 (28.0) | 0.843 |
 Carboplatin | 87 (72.5) | 28 (73.7) | 59 (72.0) |  |
PD-L1 TPS | ||||
  < 1% | 32 (26.7) | 10 (26.3) | 22 (26.8) | 0.370 |
 1–49% | 21 (17.5) | 4 (10.5) | 17 (20.7) |  |
  ≥ 50% | 32 (26.7) | 12 (31.6) | 20 (24.3) | |
 Unkown | 35 (29.2) | 12 (31.5) | 23 (28.0) | |
Response to induction therapy | ||||
 Partial response | 55 (45.8) | 12 (31.6) | 43 (52.4) | 0.033 |
 Stable disease | 65 (54.2) | 26 (68.4) | 39 (47.6) |  |
 Cycles of induction therapy Median (range) | 4 (4–6) | 4 (4–6) | 4 (4–6) | – |